Literature DB >> 3680482

Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma.

C M Mendel1, P H Frost, S T Kunitake, R R Cavalieri.   

Abstract

The iv administration of heparin causes an increase in the plasma free T4 concentration, as determined by equilibrium dialysis. The mechanism and physiological consequences of this action of heparin are unknown. To explore the possibility that the heparin-induced increase in plasma free T4 is an in vitro artifact due to generation of FFA during equilibrium dialysis, we studied plasma samples from 10 subjects treated with iv heparin. In plasma from 4 of these subjects, free T4 concentrations measured by equilibrium dialysis did not increase above baseline values after heparin administration. In incubations performed in parallel with the equilibrium dialysis measurements, FFA concentrations in these plasma samples were found to increase, but in no subject did they exceed 2.5 meq/L after incubation. In contrast, in plasma from the other 6 subjects treated with heparin, free T4 concentrations rose markedly (by 130-520%) above baseline values after heparin administration. In all of these postheparin plasma samples, FFA concentrations were less than 2.8 meq/L before incubation, but rose during incubation by 80-270% to more than 3.8 meq/L. Treatment of these plasma samples with protamine to inhibit lipoprotein lipase and with specific antiserum to inhibit hepatic triglyceride lipase before equilibrium dialysis or incubation prevented, in parallel, the heparin-induced increases in FFA and free T4 concentrations. From these findings we conclude that the heparin-induced increase in free T4 is usually an in vitro artifact, and that most subjects receiving heparin have a normal plasma free T4 concentration in vivo. We also conclude that this in vitro artifact may account for many of the findings that led to the postulate of an inhibitor of T4 binding to plasma and intracellular proteins in heparin-treated patients and perhaps in patients with nonthyroid illness as well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680482     DOI: 10.1210/jcem-65-6-1259

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Thyroid Dysfunction and COVID-19: The Emerging Role of Selenium in This Intermingled Relationship.

Authors:  Francesca Gorini; Laura Sabatino; Alessio Coi; Giorgio Iervasi; Cristina Vassalle
Journal:  Int J Environ Res Public Health       Date:  2022-06-05       Impact factor: 4.614

2.  Interferences in immunoassay.

Authors:  Jill Tate; Greg Ward
Journal:  Clin Biochem Rev       Date:  2004-05

3.  Assessment of thyroid function: towards an integrated laboratory--clinical approach.

Authors:  Jim Stockigt
Journal:  Clin Biochem Rev       Date:  2003-11

Review 4.  The clinician and the thyroid.

Authors:  H J Biersack; A Hotze
Journal:  Eur J Nucl Med       Date:  1991

Review 5.  [Non-thyroid illness" or changed thyroid hormone parameter syndrome with non-thyroid illnesses].

Authors:  W Reinhardt; K Mann
Journal:  Med Klin (Munich)       Date:  1998-11-15

Review 6.  The cytokine storm and thyroid hormone changes in COVID-19.

Authors:  L Croce; D Gangemi; G Ancona; F Liboà; G Bendotti; L Minelli; L Chiovato
Journal:  J Endocrinol Invest       Date:  2021-02-09       Impact factor: 4.256

7.  Wide Spectrum of Thyroid Function Tests in COVID-19: From Nonthyroidal Illness to Isolated Hyperthyroxinemia.

Authors:  Sima Hashemipour; Pouria Shahsavari; Somaieh Kiani; Milad Badri; Arefeh Ghobadi; Seyyed Mohammad Reza Hadizadeh Khairkhahan; Alireza Tariverdi
Journal:  Int J Endocrinol Metab       Date:  2022-01-25

8.  Subclinical Hypothyroidism Presenting as Myxedema Coma: Case Report and Literature Review.

Authors:  Tsering Dolkar; Michlene Zouetr; Malavika Shankar; Aditya Keerthi Rayapureddy; Zewge Shiferaw-Deribe
Journal:  Cureus       Date:  2022-06-01

Review 9.  Pitfalls in the measurement and interpretation of thyroid function tests.

Authors:  Olympia Koulouri; Carla Moran; David Halsall; Krishna Chatterjee; Mark Gurnell
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-10-17       Impact factor: 4.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.